カテゴリー： Market Monitor Global, 世界, 医療/バイオ

がん用個別化医療の世界市場見通し2023年-2029年

◆英語タイトル：Personalized Medicine for Cancer Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5891）

◆商品コード：MMG23JU5891
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月
◆ページ数：68
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Personalized Medicine for Cancer Market 調査レポートは次の情報を含め、グローバルにおけるのがん用個別化医療市場規模と予測を収録しています。・世界のがん用個別化医療市場：売上、2018年-2023年、2024年-2029年
・世界のがん用個別化医療市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のがん用個別化医療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「免疫療法」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

がん用個別化医療のグローバル主要企業は、Bayer、 GlaxoSmithKline、 Novartis、 Sanofi、 Pfizer、 Amgen、 Merck、 Bristol-Myers Squibb、 Ariad Pharmaceuticals (Takeda)、 Eli Lilly、 Roche、 Boehringer Ingelheim、 Johnson and Johnson、 Teva Pharmaceuticalsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、がん用個別化医療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界のがん用個別化医療市場：タイプ別、2018年-2023年、2024年-2029年
世界のがん用個別化医療市場：タイプ別市場シェア、2022年
・免疫療法、標的療法、化学療法、ホルモン療法、その他

世界のがん用個別化医療市場：用途別、2018年-2023年、2024年-2029年
世界のがん用個別化医療市場：用途別市場シェア、2022年
・乳がん、血液がん、消化器がん、前立腺がん、皮膚がん、肺がん、その他

世界のがん用個別化医療市場：地域・国別、2018年-2023年、2024年-2029年
世界のがん用個別化医療市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業におけるがん用個別化医療のグローバル売上、2018年-2023年
・主要企業におけるがん用個別化医療のグローバル売上シェア、2022年
・主要企業におけるがん用個別化医療のグローバル販売量、2018年-2023年
・主要企業におけるがん用個別化医療のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Bayer、 GlaxoSmithKline、 Novartis、 Sanofi、 Pfizer、 Amgen、 Merck、 Bristol-Myers Squibb、 Ariad Pharmaceuticals (Takeda)、 Eli Lilly、 Roche、 Boehringer Ingelheim、 Johnson and Johnson、 Teva Pharmaceuticals

*************************************************************

・調査・分析レポートの概要
がん用個別化医療市場の定義
市場セグメント
世界のがん用個別化医療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のがん用個別化医療市場規模
世界のがん用個別化医療市場規模：2022年 VS 2029年
世界のがん用個別化医療市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのがん用個別化医療の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のがん用個別化医療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：免疫療法、標的療法、化学療法、ホルモン療法、その他
がん用個別化医療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：乳がん、血液がん、消化器がん、前立腺がん、皮膚がん、肺がん、その他
がん用個別化医療の用途別グローバル売上・予測

・地域別市場分析
地域別がん用個別化医療市場規模 2022年と2029年
地域別がん用個別化医療売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Bayer、 GlaxoSmithKline、 Novartis、 Sanofi、 Pfizer、 Amgen、 Merck、 Bristol-Myers Squibb、 Ariad Pharmaceuticals (Takeda)、 Eli Lilly、 Roche、 Boehringer Ingelheim、 Johnson and Johnson、 Teva Pharmaceuticals
...

This report aims to provide a comprehensive presentation of the global market for Personalized Medicine for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Personalized Medicine for Cancer. This report contains market size and forecasts of Personalized Medicine for Cancer in global, including the following market information:
Global Personalized Medicine for Cancer Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Personalized Medicine for Cancer market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Immunotherapy Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Personalized Medicine for Cancer include Bayer, GlaxoSmithKline, Novartis, Sanofi, Pfizer, Amgen, Merck, Bristol-Myers Squibb and Ariad Pharmaceuticals (Takeda), etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Personalized Medicine for Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Personalized Medicine for Cancer Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Personalized Medicine for Cancer Market Segment Percentages, by Type, 2022 (%)
Immunotherapy
Targeted Therapy
Chemotherapy
Hormone Therapy
Others
Global Personalized Medicine for Cancer Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Personalized Medicine for Cancer Market Segment Percentages, by Application, 2022 (%)
Breast Cancer
Blood Cancer
Gastrointestinal Cancer
Prostate Cancer
Skin Cancer
Lung Cancer
Others
Global Personalized Medicine for Cancer Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Personalized Medicine for Cancer Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Personalized Medicine for Cancer revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Personalized Medicine for Cancer revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
GlaxoSmithKline
Novartis
Sanofi
Pfizer
Amgen
Merck
Bristol-Myers Squibb
Ariad Pharmaceuticals (Takeda)
Eli Lilly
Roche
Boehringer Ingelheim
Johnson and Johnson
Teva Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Personalized Medicine for Cancer, market overview.
Chapter 2: Global Personalized Medicine for Cancer market size in revenue.
Chapter 3: Detailed analysis of Personalized Medicine for Cancer company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Personalized Medicine for Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Personalized Medicine for Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Personalized Medicine for Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Personalized Medicine for Cancer Overall Market Size
2.1 Global Personalized Medicine for Cancer Market Size: 2022 VS 2029
2.2 Global Personalized Medicine for Cancer Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Personalized Medicine for Cancer Players in Global Market
3.2 Top Global Personalized Medicine for Cancer Companies Ranked by Revenue
3.3 Global Personalized Medicine for Cancer Revenue by Companies
3.4 Top 3 and Top 5 Personalized Medicine for Cancer Companies in Global Market, by Revenue in 2022
3.5 Global Companies Personalized Medicine for Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Personalized Medicine for Cancer Players in Global Market
3.6.1 List of Global Tier 1 Personalized Medicine for Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 Personalized Medicine for Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Personalized Medicine for Cancer Market Size Markets, 2022 & 2029
4.1.2 Immunotherapy
4.1.3 Targeted Therapy
4.1.4 Chemotherapy
4.1.5 Hormone Therapy
4.1.6 Others
4.2 By Type – Global Personalized Medicine for Cancer Revenue & Forecasts
4.2.1 By Type – Global Personalized Medicine for Cancer Revenue, 2018-2023
4.2.2 By Type – Global Personalized Medicine for Cancer Revenue, 2024-2029
4.2.3 By Type – Global Personalized Medicine for Cancer Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Personalized Medicine for Cancer Market Size, 2022 & 2029
5.1.2 Breast Cancer
5.1.3 Blood Cancer
5.1.4 Gastrointestinal Cancer
5.1.5 Prostate Cancer
5.1.6 Skin Cancer
5.1.7 Lung Cancer
5.1.8 Others
5.2 By Application – Global Personalized Medicine for Cancer Revenue & Forecasts
5.2.1 By Application – Global Personalized Medicine for Cancer Revenue, 2018-2023
5.2.2 By Application – Global Personalized Medicine for Cancer Revenue, 2024-2029
5.2.3 By Application – Global Personalized Medicine for Cancer Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Personalized Medicine for Cancer Market Size, 2022 & 2029
6.2 By Region – Global Personalized Medicine for Cancer Revenue & Forecasts
6.2.1 By Region – Global Personalized Medicine for Cancer Revenue, 2018-2023
6.2.2 By Region – Global Personalized Medicine for Cancer Revenue, 2024-2029
6.2.3 By Region – Global Personalized Medicine for Cancer Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Personalized Medicine for Cancer Revenue, 2018-2029
6.3.2 US Personalized Medicine for Cancer Market Size, 2018-2029
6.3.3 Canada Personalized Medicine for Cancer Market Size, 2018-2029
6.3.4 Mexico Personalized Medicine for Cancer Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Personalized Medicine for Cancer Revenue, 2018-2029
6.4.2 Germany Personalized Medicine for Cancer Market Size, 2018-2029
6.4.3 France Personalized Medicine for Cancer Market Size, 2018-2029
6.4.4 U.K. Personalized Medicine for Cancer Market Size, 2018-2029
6.4.5 Italy Personalized Medicine for Cancer Market Size, 2018-2029
6.4.6 Russia Personalized Medicine for Cancer Market Size, 2018-2029
6.4.7 Nordic Countries Personalized Medicine for Cancer Market Size, 2018-2029
6.4.8 Benelux Personalized Medicine for Cancer Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Personalized Medicine for Cancer Revenue, 2018-2029
6.5.2 China Personalized Medicine for Cancer Market Size, 2018-2029
6.5.3 Japan Personalized Medicine for Cancer Market Size, 2018-2029
6.5.4 South Korea Personalized Medicine for Cancer Market Size, 2018-2029
6.5.5 Southeast Asia Personalized Medicine for Cancer Market Size, 2018-2029
6.5.6 India Personalized Medicine for Cancer Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Personalized Medicine for Cancer Revenue, 2018-2029
6.6.2 Brazil Personalized Medicine for Cancer Market Size, 2018-2029
6.6.3 Argentina Personalized Medicine for Cancer Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Personalized Medicine for Cancer Revenue, 2018-2029
6.7.2 Turkey Personalized Medicine for Cancer Market Size, 2018-2029
6.7.3 Israel Personalized Medicine for Cancer Market Size, 2018-2029
6.7.4 Saudi Arabia Personalized Medicine for Cancer Market Size, 2018-2029
6.7.5 UAE Personalized Medicine for Cancer Market Size, 2018-2029
7 Personalized Medicine for Cancer Companies Profiles
7.1 Bayer
7.1.1 Bayer Company Summary
7.1.2 Bayer Business Overview
7.1.3 Bayer Personalized Medicine for Cancer Major Product Offerings
7.1.4 Bayer Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.1.5 Bayer Key News & Latest Developments
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Company Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Personalized Medicine for Cancer Major Product Offerings
7.2.4 GlaxoSmithKline Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.2.5 GlaxoSmithKline Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Personalized Medicine for Cancer Major Product Offerings
7.3.4 Novartis Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 Sanofi
7.4.1 Sanofi Company Summary
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Personalized Medicine for Cancer Major Product Offerings
7.4.4 Sanofi Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.4.5 Sanofi Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Personalized Medicine for Cancer Major Product Offerings
7.5.4 Pfizer Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 Amgen
7.6.1 Amgen Company Summary
7.6.2 Amgen Business Overview
7.6.3 Amgen Personalized Medicine for Cancer Major Product Offerings
7.6.4 Amgen Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.6.5 Amgen Key News & Latest Developments
7.7 Merck
7.7.1 Merck Company Summary
7.7.2 Merck Business Overview
7.7.3 Merck Personalized Medicine for Cancer Major Product Offerings
7.7.4 Merck Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.7.5 Merck Key News & Latest Developments
7.8 Bristol-Myers Squibb
7.8.1 Bristol-Myers Squibb Company Summary
7.8.2 Bristol-Myers Squibb Business Overview
7.8.3 Bristol-Myers Squibb Personalized Medicine for Cancer Major Product Offerings
7.8.4 Bristol-Myers Squibb Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.8.5 Bristol-Myers Squibb Key News & Latest Developments
7.9 Ariad Pharmaceuticals (Takeda)
7.9.1 Ariad Pharmaceuticals (Takeda) Company Summary
7.9.2 Ariad Pharmaceuticals (Takeda) Business Overview
7.9.3 Ariad Pharmaceuticals (Takeda) Personalized Medicine for Cancer Major Product Offerings
7.9.4 Ariad Pharmaceuticals (Takeda) Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.9.5 Ariad Pharmaceuticals (Takeda) Key News & Latest Developments
7.10 Eli Lilly
7.10.1 Eli Lilly Company Summary
7.10.2 Eli Lilly Business Overview
7.10.3 Eli Lilly Personalized Medicine for Cancer Major Product Offerings
7.10.4 Eli Lilly Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.10.5 Eli Lilly Key News & Latest Developments
7.11 Roche
7.11.1 Roche Company Summary
7.11.2 Roche Business Overview
7.11.3 Roche Personalized Medicine for Cancer Major Product Offerings
7.11.4 Roche Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.11.5 Roche Key News & Latest Developments
7.12 Boehringer Ingelheim
7.12.1 Boehringer Ingelheim Company Summary
7.12.2 Boehringer Ingelheim Business Overview
7.12.3 Boehringer Ingelheim Personalized Medicine for Cancer Major Product Offerings
7.12.4 Boehringer Ingelheim Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.12.5 Boehringer Ingelheim Key News & Latest Developments
7.13 Johnson and Johnson
7.13.1 Johnson and Johnson Company Summary
7.13.2 Johnson and Johnson Business Overview
7.13.3 Johnson and Johnson Personalized Medicine for Cancer Major Product Offerings
7.13.4 Johnson and Johnson Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.13.5 Johnson and Johnson Key News & Latest Developments
7.14 Teva Pharmaceuticals
7.14.1 Teva Pharmaceuticals Company Summary
7.14.2 Teva Pharmaceuticals Business Overview
7.14.3 Teva Pharmaceuticals Personalized Medicine for Cancer Major Product Offerings
7.14.4 Teva Pharmaceuticals Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.14.5 Teva Pharmaceuticals Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Personalized Medicine for Cancer Market Opportunities & Trends in Global Market
Table 2. Personalized Medicine for Cancer Market Drivers in Global Market
Table 3. Personalized Medicine for Cancer Market Restraints in Global Market
Table 4. Key Players of Personalized Medicine for Cancer in Global Market
Table 5. Top Personalized Medicine for Cancer Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Personalized Medicine for Cancer Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Personalized Medicine for Cancer Revenue Share by Companies, 2018-2023
Table 8. Global Companies Personalized Medicine for Cancer Product Type
Table 9. List of Global Tier 1 Personalized Medicine for Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Personalized Medicine for Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Personalized Medicine for Cancer Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Personalized Medicine for Cancer Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Personalized Medicine for Cancer Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Personalized Medicine for Cancer Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Personalized Medicine for Cancer Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Personalized Medicine for Cancer Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Personalized Medicine for Cancer Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Personalized Medicine for Cancer Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Personalized Medicine for Cancer Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Personalized Medicine for Cancer Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Personalized Medicine for Cancer Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Personalized Medicine for Cancer Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Personalized Medicine for Cancer Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Personalized Medicine for Cancer Revenue, (US$, Mn), 2024-2029
Table 30. Bayer Company Summary
Table 31. Bayer Personalized Medicine for Cancer Product Offerings
Table 32. Bayer Personalized Medicine for Cancer Revenue (US$, Mn) & (2018-2023)
Table 33. Bayer Key News & Latest Developments
Table 34. GlaxoSmithKline Company Summary
Table 35. GlaxoSmithKline Personalized Medicine for Cancer Product Offerings
Table 36. GlaxoSmithKline Personalized Medicine for Cancer Revenue (US$, Mn) & (2018-2023)
Table 37. GlaxoSmithKline Key News & Latest Developments
Table 38. Novartis Company Summary
Table 39. Novartis Personalized Medicine for Cancer Product Offerings
Table 40. Novartis Personalized Medicine for Cancer Revenue (US$, Mn) & (2018-2023)
Table 41. Novartis Key News & Latest Developments
Table 42. Sanofi Company Summary
Table 43. Sanofi Personalized Medicine for Cancer Product Offerings
Table 44. Sanofi Personalized Medicine for Cancer Revenue (US$, Mn) & (2018-2023)
Table 45. Sanofi Key News & Latest Developments
Table 46. Pfizer Company Summary
Table 47. Pfizer Personalized Medicine for Cancer Product Offerings
Table 48. Pfizer Personalized Medicine for Cancer Revenue (US$, Mn) & (2018-2023)
Table 49. Pfizer Key News & Latest Developments
Table 50. Amgen Company Summary
Table 51. Amgen Personalized Medicine for Cancer Product Offerings
Table 52. Amgen Personalized Medicine for Cancer Revenue (US$, Mn) & (2018-2023)
Table 53. Amgen Key News & Latest Developments
Table 54. Merck Company Summary
Table 55. Merck Personalized Medicine for Cancer Product Offerings
Table 56. Merck Personalized Medicine for Cancer Revenue (US$, Mn) & (2018-2023)
Table 57. Merck Key News & Latest Developments
Table 58. Bristol-Myers Squibb Company Summary
Table 59. Bristol-Myers Squibb Personalized Medicine for Cancer Product Offerings
Table 60. Bristol-Myers Squibb Personalized Medicine for Cancer Revenue (US$, Mn) & (2018-2023)
Table 61. Bristol-Myers Squibb Key News & Latest Developments
Table 62. Ariad Pharmaceuticals (Takeda) Company Summary
Table 63. Ariad Pharmaceuticals (Takeda) Personalized Medicine for Cancer Product Offerings
Table 64. Ariad Pharmaceuticals (Takeda) Personalized Medicine for Cancer Revenue (US$, Mn) & (2018-2023)
Table 65. Ariad Pharmaceuticals (Takeda) Key News & Latest Developments
Table 66. Eli Lilly Company Summary
Table 67. Eli Lilly Personalized Medicine for Cancer Product Offerings
Table 68. Eli Lilly Personalized Medicine for Cancer Revenue (US$, Mn) & (2018-2023)
Table 69. Eli Lilly Key News & Latest Developments
Table 70. Roche Company Summary
Table 71. Roche Personalized Medicine for Cancer Product Offerings
Table 72. Roche Personalized Medicine for Cancer Revenue (US$, Mn) & (2018-2023)
Table 73. Roche Key News & Latest Developments
Table 74. Boehringer Ingelheim Company Summary
Table 75. Boehringer Ingelheim Personalized Medicine for Cancer Product Offerings
Table 76. Boehringer Ingelheim Personalized Medicine for Cancer Revenue (US$, Mn) & (2018-2023)
Table 77. Boehringer Ingelheim Key News & Latest Developments
Table 78. Johnson and Johnson Company Summary
Table 79. Johnson and Johnson Personalized Medicine for Cancer Product Offerings
Table 80. Johnson and Johnson Personalized Medicine for Cancer Revenue (US$, Mn) & (2018-2023)
Table 81. Johnson and Johnson Key News & Latest Developments
Table 82. Teva Pharmaceuticals Company Summary
Table 83. Teva Pharmaceuticals Personalized Medicine for Cancer Product Offerings
Table 84. Teva Pharmaceuticals Personalized Medicine for Cancer Revenue (US$, Mn) & (2018-2023)
Table 85. Teva Pharmaceuticals Key News & Latest Developments
List of Figures
Figure 1. Personalized Medicine for Cancer Segment by Type in 2022
Figure 2. Personalized Medicine for Cancer Segment by Application in 2022
Figure 3. Global Personalized Medicine for Cancer Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Personalized Medicine for Cancer Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Personalized Medicine for Cancer Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Personalized Medicine for Cancer Revenue in 2022
Figure 8. By Type - Global Personalized Medicine for Cancer Revenue Market Share, 2018-2029
Figure 9. By Application - Global Personalized Medicine for Cancer Revenue Market Share, 2018-2029
Figure 10. By Type - Global Personalized Medicine for Cancer Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Personalized Medicine for Cancer Revenue Market Share, 2018-2029
Figure 12. By Application - Global Personalized Medicine for Cancer Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Personalized Medicine for Cancer Revenue Market Share, 2018-2029
Figure 14. By Region - Global Personalized Medicine for Cancer Revenue Market Share, 2018-2029
Figure 15. By Country - North America Personalized Medicine for Cancer Revenue Market Share, 2018-2029
Figure 16. US Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Personalized Medicine for Cancer Revenue Market Share, 2018-2029
Figure 20. Germany Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 21. France Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Personalized Medicine for Cancer Revenue Market Share, 2018-2029
Figure 28. China Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 32. India Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Personalized Medicine for Cancer Revenue Market Share, 2018-2029
Figure 34. Brazil Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Personalized Medicine for Cancer Revenue Market Share, 2018-2029
Figure 37. Turkey Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Personalized Medicine for Cancer Revenue, (US$, Mn), 2018-2029
Figure 41. Bayer Personalized Medicine for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. GlaxoSmithKline Personalized Medicine for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Novartis Personalized Medicine for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Sanofi Personalized Medicine for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Pfizer Personalized Medicine for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Amgen Personalized Medicine for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Merck Personalized Medicine for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Bristol-Myers Squibb Personalized Medicine for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Ariad Pharmaceuticals (Takeda) Personalized Medicine for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Eli Lilly Personalized Medicine for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Roche Personalized Medicine for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Boehringer Ingelheim Personalized Medicine for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Johnson and Johnson Personalized Medicine for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Teva Pharmaceuticals Personalized Medicine for Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ がん用個別化医療の世界市場見通し2023年-2029年(Personalized Medicine for Cancer Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

がん用個別化医療の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp